Sanofi has been extremely active in the biotech market, highlighted by its breakthroughs and significant partnerships. Notably
Sanofi Modulus was touted as one of the Best Inventions of 2025 while the company signed a pivotal deal with Canadian tech firm to incorporate artificial intelligence in its R&D activities. Concurrently, Sanofi’s
SAR446597 study offers potential game-changing effects for age-related macular degeneration. The company allocated
$110M to radioligand therapy that has successfully crossed phase 2 tumor trial. On the downside, British officials remain skeptical about the pharmaceutical market place, potentially limiting the company's scope of business.
Novavax experienced an 11.9% drop in its shares after Sanofi took over EU marketing of Nuvaxovid Vaccine. Another highlight is Sanofi's $625M investment to nourish young biotechs and digital health startups. Sanofi ran into regulatory issues when it came under investigation by European Commission over vaccines. On a promising note,
Sanofi's AlphaMedix study touched key milestones in the phase 2 study, signaling steady progress. There were setbacks, though, faced by
Sanofi's MS hopeful
tolebrutinib that experienced a delay in FDA approval. Lastly, Sanofi expressed plans to buy US biopharma group Blueprint for approximately $9.5 billion.
Sanofi News Analytics from Mon, 06 Jan 2025 08:00:00 GMT to Sat, 11 Oct 2025 17:20:21 GMT -
Rating 5
- Innovation 7
- Information -1
- Rumor 3
